secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2026-06-30T23:43:20+00:00
Accession:  0001171843-26-004406
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; deal closed
--------------------------------------------------------------------------------

- Aptose shareholders receive C$2.41 per share, a 28% premium over 30-day VWAP of C$1.88.
- Acquisition by Hanmi Pharmaceutical closed; all outstanding shares not owned by Hanmi acquired.
- Shareholder and court approvals obtained on March 31, 2026; Korean regulatory approvals received.
- Common shares to be delisted from TSX on or about July 3, 2026; company to cease public reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184326004406/0001171843-26-004406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184326004406/f8k_063026.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer